Actively Recruiting

Phase Not Applicable
Age: 18Years - 99Years
All Genders
NCT04474106

NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After Injury

Led by AUVA · Updated on 2024-02-01

246

Participants Needed

15

Research Sites

339 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

It has been hypothesized that there are two mechanisms of acute traumatic spinal cord injury (SCI): the primary mechanical damage and the secondary injury due to additional pathological processes initiated by the primary injury. Neurological damage due to laceration, contusion, distraction or compression of the spinal cord is called ''primary injury''. This mechanical injury leads to a cascade of biochemical and pathological changes, described as ''secondary injury'', which occurs minutes to weeks after the initial trauma and causes further neurological deterioration. This secondary cascade involves vascular changes, an inflammatory response, neurotoxicity, apoptosis and glial scarring, and further compromises neurological impairment after traumatic spinal cord injury. Edema, ischemia and loss of autoregulation continue to spread bi-directionally from the initial lesion along the spinal cord for up to 72 hours after the trauma. It has been postulated that the damage caused by the primary injury mechanism is irreversible and therapeutic approaches in recent years have focused on modulating the secondary injury cascade. Researchers found significantly greater numbers of myelinated fibers in peripheral nerves after a single ESWT application in an experimental model on rats after a homotopic nerve autograft into the sciatic nerve. In another study a spinal cord ischemia model in mice was performed. ESWT was applied immediately after surgery and the treated animals showed a significantly better motor function and decreased neuronal degeneration compared to the control group within the first 7 days after surgery. Researchers investigated the effect of low-energy ESWT for the duration of three weeks on a thoracic spinal cord contusion injury model in rats. Animals in the ESWT group demonstrated significantly better locomotor improvement and reduced neuronal loss compared to the control animals at 7, 35, and 42 days after contusion. It has been postulated previously, that ESWT improves the metabolic activity of various cell types and induces an improved rate of axonal regeneration. ESWT might be a promising therapeutic strategy in the treatment of traumatic SCI. The underlying study aims to investigate the effect of ESWT after acute traumatic spinal cord injury in humans within 48 hours of trauma in order to intervene in the secondary injury phase with the objective to reduce the extent of neuronal damage.

CONDITIONS

Official Title

NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After Injury

Who Can Participate

Age: 18Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with acute traumatic spinal injuries who are awake, responsive, and oriented at admission
  • Patients from the age of 18 years
  • Admission to hospital within 24 hours after injury
  • Written consent to participate in the study
  • Participation in the Austrian Spinal Cord Injury Study (ASCIS)-Registry (only for the Austrian hospitals)
Not Eligible

You will not qualify if you...

  • Patients who cannot cooperate or are not capable to give consent to participate
  • Serious traumatic brain injuries that prevent accurate participation in study procedures and/or adequacy of informed consent
  • Participation in other interventional clinical trials
  • Serious concomitant injuries that prevent the neurological initial assessment
  • Preexisting neurological conditions that affect the primary endpoint of the study and potentially mask or reduce the therapeutic effect of the ESWT application
  • High dose administration of corticosteroids
  • Complete spinal cord transection
  • Patients with pacemakers or implantable defibrillators
  • Patients who are using devices which are sensitive to electromagnetic radiation
  • (potential) Pregnancy
  • Patients with tumors
  • Patients with severe coagulation disorders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

Medical University Innsbruck

Innsbruck, Tyrol, Austria, 6020

Actively Recruiting

2

Rehazentrum Bad Häring

Bad Häring, Austria, 6323

Active, Not Recruiting

3

Landeskarnkenhaus Feldkirch

Feldkirch, Austria, 6807

Actively Recruiting

4

Unfallkrankenhaus Graz

Graz, Austria, 8020

Actively Recruiting

5

Rehazentrum Tobelbad

Graz, Austria, 8144

Active, Not Recruiting

6

Unfallkrankenhaus Klagenfurt

Klagenfurt, Austria, 9020

Actively Recruiting

7

Rehazentrum Weißer Hof

Klosterneuburg, Austria, 3400

Active, Not Recruiting

8

Unfallkrankenhaus Linz

Linz, Austria, 4010

Actively Recruiting

9

Unfallkrankenhaus Salzburg

Salzburg, Austria, 5010

Actively Recruiting

10

Universitätsklinik für Orthopädie und Traumatologie

Salzburg, Austria, 5020

Withdrawn

11

Unfallkrankenhaus St. Pölten

Sankt Pölten, Austria, 3100

Withdrawn

12

Universitätsklinik Wien, AKH

Vienna, Austria, 1090

Actively Recruiting

13

Unfallkrankenhaus Meidling

Vienna, Austria, 1120

Actively Recruiting

14

Unfallkrankenhaus Lorenz Böhler

Vienna, Austria, 1200

Withdrawn

15

SMZ Ost, Donauspital Abteilung für Unfallchirurgie

Vienna, Austria, 1220

Not Yet Recruiting

Loading map...

Research Team

W

Wolfgang Schaden, Dr

CONTACT

I

Iris Leister, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After Injury | DecenTrialz